Frontiers in Oncology | Cancer Immunity and Immunotherapy

Case Report

Published on 03 Nov 2025

Nivolumab-induced subacute cutaneous lupus erythematosus in a patient with sigmoid colon cancer: a case report and review of the literature

in Cancer Immunity and Immunotherapy

Li Chang
Jianglin Zhang
Zhaojun Sun
Youyou Zhou
Lixiong Zheng

Frontiers in Oncology

doi 10.3389/fonc.2025.1674823

401 views

Case Report

Published on 03 Nov 2025

Complete response of advanced HER2-amplified lung adenocarcinoma to cadonilimab combined with disitamab vedotin: a case report

in Cancer Immunity and Immunotherapy

Yue Li
Keru Ma
Hao Wang
Zongying Liu
Zhuying Li

Frontiers in Oncology

doi 10.3389/fonc.2025.1587210

158 views

Case Report

Published on 03 Nov 2025

Case Report: Two cases of immune-associated myocarditis caused by tislelizumab

in Cancer Immunity and Immunotherapy

Jie Zhao
Jinliang Wan
Shan Wang
Shuyue Zhang
Yanzhang Hao

Frontiers in Oncology

doi 10.3389/fonc.2025.1549141

352 views

Original Research

Accepted on 31 Oct 2025

Toripalimab plus gemcitabine and cisplatin induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma (LANPC): A retrospective study

in Cancer Immunity and Immunotherapy

Renba Liang
Ling Lei
Xinxiao Li
Fengming Lan
Fangmeng Fu
Teng Zou
Li Ma
Peng Chen
Zhanmei wang
Jing Jin

Frontiers in Oncology

Original Research

Accepted on 31 Oct 2025

Redox phenotype confers T cell-exclusion microenvironment and resistance to immunotherapy by suppressing STING/MDA5 expression and interferon signaling in lung cancers harboring KEAP1/STK11 mutations

in Cancer Immunity and Immunotherapy

Ziying Lin
SHRESTHA ASHISH
Jincui Gu
Lixia Huang
Shaoli Li
Yangchan Li
Yanbin Zhou

Frontiers in Oncology

Systematic Review

Accepted on 31 Oct 2025

First-Line Immunochemotherapy for Advanced NSCLC in Asian Patients: A Meta-Analysis of Phase 3 RCTs

in Cancer Immunity and Immunotherapy

Zhifang Mao
Zhiyong Zhang
Meijiao Song
Jiaqi He
Jing Zheng
Wenquan Liu

Frontiers in Oncology

Original Research

Accepted on 31 Oct 2025

Frailty Trajectories and Their Determinants in Cancer Patients Undergoing Immunotherapy: A Prospective Longitudinal Study

in Cancer Immunity and Immunotherapy

Wei Zhu
Juan Ji

Frontiers in Oncology

Case Report

Published on 31 Oct 2025

Case Report: IL-6 suppression: a potential strategy for mitigating severe immune-related adverse events in nivolumab and ipilimumab therapy for malignant pleural mesothelioma

in Cancer Immunity and Immunotherapy

Asako Yanagisawa
Takumi Fukaya
Kento Noda
Hiroshi Kojima
Hidefumi Shimizu

Frontiers in Oncology

doi 10.3389/fonc.2025.1671503

292 views

Mini Review

Published on 31 Oct 2025

Decoding the immune microenvironment in osteosarcoma: new insights into checkpoints, vaccines, and CAR-T cells

in Cancer Immunity and Immunotherapy

Haitian Wang
Tongtong Zhu
Kunpeng Yang
Chenkai Xu
Zhaoyi Zhang
Guangyao Liu
Hongge Ren

Frontiers in Oncology

doi 10.3389/fonc.2025.1702219

256 views

Original Research

Published on 30 Oct 2025

Dual oncogenic role of RNF220 in AML: linking metabolic rewiring to cell proliferation and immune evasion

in Cancer Immunity and Immunotherapy

Bixia Li
Shi Jiang
Yao Xu
Xiao Yan
Qitian Mu
Guifang Ouyang

Frontiers in Oncology

doi 10.3389/fonc.2025.1670895

200 views

Original Research

Accepted on 29 Oct 2025

First-line Immune Checkpoint Inhibitors Combined with Chemotherapy in Advanced Large-cell Neuroendocrine Carcinoma of the Lung: A Real-world Retrospective Study

in Cancer Immunity and Immunotherapy

Beibei Ji
Wei Luan
Rula Sha
Wenxin Li

Frontiers in Oncology

139 views

Systematic Review

Published on 29 Oct 2025

Navigating the risks: a systematic review of immune checkpoint inhibitor therapy before liver transplant for hepatocellular carcinoma and its impact on allograft rejection and survival outcomes

in Cancer Immunity and Immunotherapy

Donghua Liu
Xinyi Wang
Xuelian Liu
Jing Li

Frontiers in Oncology

doi 10.3389/fonc.2025.1689820

424 views

Review

Published on 29 Oct 2025

Antibody–drug conjugate: a newly developed biological missile for tumor treatment

in Cancer Immunity and Immunotherapy

Zhuoran Tang
Yanchun Xie
Yanping Zeng

Frontiers in Oncology

doi 10.3389/fonc.2025.1688057

1,102 views

Original Research

Accepted on 28 Oct 2025

Association Between Immune-Related Adverse Events and Recurrence Dynamics Under Adjuvant Anti– PD-1 Therapy in Resected Melanoma

in Cancer Immunity and Immunotherapy

Gökhan Şahin
CANER ACAR
Haydar Çağatay Yüksel
Salih Tünbekici
Pınar Açar
Banu Yaman
Burcak Karaca

Frontiers in Oncology

132 views

Original Research

Accepted on 28 Oct 2025

Phytochemical and Nanoparticle-Based Therapeutic Potential of Sphaeranthus indicus Against Hepatocellular Carcinoma via Cryptomeridiol Targeting

in Cancer Immunity and Immunotherapy

Ritika Ravindra Konduskar
Abhinandan Patil
Somnath Bhinge
Gourav Rameshlal Chawla
Yash B. Yadav

Frontiers in Oncology

Original Research

Accepted on 28 Oct 2025

Early C-Reactive Protein Reduction Predicts Survival in Real-World Extensive-Stage Small Cell Lung Cancer Treated with First-Line Adebrelimab-Based Immunotherapy

in Cancer Immunity and Immunotherapy

Jian Wang
Xueli Zhang
Qijia Gao
Jianxin Chen

Frontiers in Oncology

100 views